{
  "docId": "019dd923-5e88-73ef-bd5b-14c31e0c6f76",
  "docSlug": "71f6bd7b1ee963b8",
  "documentTitle": "250115 ucb company presentation jpm",
  "authorId": "JPMorgan",
  "authorName": "UCB",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 9,
  "pageCount": 13,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "key_takeaways",
  "function": "quantify_impact",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a line chart to show weekly prescription volume and a comparison table to show improved insurance coverage status (before vs. Jan 2025).",
  "elementsJson": [
    "headline_text",
    "line_chart",
    "comparison_table",
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5b-14c31e0c6f76/9",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5b-14c31e0c6f76",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5b-14c31e0c6f76.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5b-14c31e0c6f76#slide-9",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Very favorable commercial coverage among all IL-17s for Psoriasis (JAN25), with zero exclusions.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-28a9-71be-806e-394a519f73a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.44,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "chart",
      "text": "BIMZELX® | Uptake vs. other interleukin antibodies Performance with 2024 Coverage**",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e8c3038-b4bf-4326-8ac6-665885ea4b4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Weekly TRx",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-28a9-71be-806e-3c96233ba06e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.44,
        "x": 0.04,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "Achieved 5 major approvals*** in only two months (SEP24 and NOV24). Enhanced patient access and reimbursement pathways continue to drive uptake",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a90a19f-2704-456c-b106-3b9890a4dad0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.44,
        "x": 0.51,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "Vast majority of Medicare & Medicaid patients with access to BIMZELX®",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d36f3c80-2f0e-4ba7-b659-01f04b698e99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.77,
        "x": 0.19,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "*As of January 2025; **2024 formulary access: BIMZELX® covered and available for 6 out of 10 commercially insured lives at double-step edit or better; ***4 indications and one additional 2mL Device Presentations; ****Commercial coverage across top payers; PsA = Psoriatic Arthritis; AS = Ankylosing Spondylitis; nr-axSpA = non-radiographic Axial Spondyloarthritis; IL = interleukin; 1st Line = no prior biologic steps required; SSE = single step edit; DSE = double step edit; UCB – 43rd Annual J.P. Morgan Healthcare Conference, 15th January 2025",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab036d27-6c7b-47c2-abf4-c243114fd3ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.51,
        "y": 0.16
      },
      "kind": "table",
      "text": "Very favorable commercial coverage among all IL-17s for Psoriasis (JAN25), with zero exclusions****",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9270fffa-95e1-4ec2-ad1a-5a2519de815c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.03,
        "y": 0.09
      },
      "kind": "title",
      "text": "Recognition of INNOVATION LEADING TO PATIENT VALUE | Significantly improved access in the U.S.*",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7083d03d-a277-4eba-8a44-4d7b317c16af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Key Growth Driver: BIMZELX®",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da8e2264-b389-4e66-a7d0-8d230a3ecfe4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 9,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "8b539f77-366c-475b-8e47-8b6ed933acc3",
      "evidence": "Slides 8-9 discuss investment in innovation and growth",
      "position": 0,
      "objective": "Highlighting the cost of inaction in investing in innovation",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}